

11<sup>th</sup> November, 2020

To,  
The Manager,  
Dept. of Corporate Services,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001

Dear Sir/Madam,

**Sub: Outcome of Board Meeting**  
**Ref: BSE Scrip Code: 511509**

We wish to inform you that the Board of Directors of the Company, at their just concluded meeting *inter alia* have transacted the following business:

1. Approved the Un-Audited Standalone Financial Results for the Second Quarter and Half year ended 30<sup>th</sup> September, 2020 as recommended by the Audit committee and Reviewed by the Statutory Auditors.
2. Approved the Un-Audited Consolidated Financial Results for the Second Quarter and Half ended 30<sup>th</sup> September, 2020 as recommended by the Audit committee and Reviewed by the Statutory Auditors.
3. Appointment of Mr. Vinay Babu Gade, (M.No. A20592, CP No. 20707) Company Secretary in Practice, as the Secretarial Auditor of the Company for the Financial Year 2020-21 to issue Secretarial Audit Report.

The meeting commenced at 6 PM and concluded at 7. 15 PM

This is for your information on record.

Thanking You  
Yours Truly

For Vivo Bio Tech Ltd



**M. Kalyan Ram**  
Whole Time Director  
DIN: 02012580



Vivo Bio Tech Ltd

8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate

Road No.1, Banjara Hills, Hyderabad-500034

E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

**Vivo Bio Tech Ltd.**  
Your Drug Discovery Partner

UNAUDITED STAND ALONE FINANCIAL RESULTS FOR THE QTR AND HALF YEAR ENDED 30TH SEPTEMBER, 2020							Rs. in Lacs
S.No.	PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		Year Ended
		30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
		Un-Audited	Un-Audited	Un - Audited	Un-Audited	Un - Audited	Audited
I	Revenue from operations	1466.53	915.40	1354.44	2381.93	2,688.99	5535.22
II	Other Income		0.00	2.93		2.93	5.32
III	<b>Total Income</b>	<b>1466.53</b>	<b>915.40</b>	<b>1357.37</b>	<b>2381.93</b>	<b>2691.92</b>	<b>5540.54</b>
IV	<b>Expenses</b>						
	a) Increase/(decrease) in stock in trade and WIP	(101.32)	90.62	-33.56	(10.70)	(129.60)	-234.23
	b) Consumption of Raw materials	0.00		0.00		0.00	0.00
	c) Purchase of traded goods	197.96	123.23	319.36	321.19	523.76	1089.97
	d) Employees Cost	258.22	157.05	255.60	415.27	477.53	999.77
	e) Depreciation and amortisation	125.90	126.42	126.45	252.32	252.89	517.16
	f) Finance Cost	102.97	70.36	75.15	173.33	162.63	309.84
	g)Administrative Expenditure	512.91	255.88	446.13	768.79	1072.65	2432.48
	<b>Total</b>	<b>1096.64</b>	<b>823.56</b>	<b>1189.13</b>	<b>1920.20</b>	<b>2359.86</b>	<b>5114.99</b>
V	Profit Before Tax (III-IV)	369.89	91.84	168.25	461.73	332.07	425.55
	Exceptional Item			0.00		0.00	0
VI	Profit Before Tax	369.89	91.84	168.25	461.73	332.07	425.55
VII	<b>Tax Expense</b>						
	a. Current Tax	73.99	18.36	19.16	92.35	82.81	112.33
	b. Deffered tax	80.45	-24.28	-84.32	56.17	(104.30)	-131.14
	<b>Total Tax Expense</b>	<b>154.43</b>	<b>(5.92)</b>	<b>(65.17)</b>	<b>148.51</b>	<b>(21.50)</b>	<b>(18.81)</b>
	<b>Net Profit After Tax (V-VI)</b>	<b>215.45</b>	<b>97.76</b>	<b>233.41</b>	<b>313.21</b>	<b>353.56</b>	<b>444.36</b>
VIII	Other Comprehensive Income						
	a.Items that will be reclassified to profit or loss (Net of Tax)	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Total other Comprehensive Income(VII+VIII+IX)</b>	<b>215.45</b>	<b>97.76</b>	<b>233.41</b>	<b>313.21</b>	<b>353.56</b>	<b>444.36</b>
X	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1288.75	1288.75	1275.05	1288.75	1275.05	1288.75
XI	<b>Earnings per equity share:</b>						
	1)Basic	1.67	0.76	1.83	2.43	2.77	3.45
	2)Diluted	1.67	0.76	1.83	2.43	2.77	3.45





Vivo Bio Tech Ltd  
 8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate  
 Road No.1, Banjara Hills, Hyderabad-500034  
 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

**Vivo Bio Tech Ltd.**  
 Your Drug Discovery Partner

**Standalone Cash Flow Statement for the Half Year Ended 30th September, 2020**

Rs. In Lacs

Particulars	As at	As at	As at
	30.09.2020	30.09.2019	31.03.2020
	Un-Audited	Un-Audited	Audited
<b>A. Cash Flow from Operating Activities:</b>			
Net Profit/ (Loss) before taxation and extraordinary items	461.73	332.00	425.55
<b>Adjustments for:</b>			
Depreciation			
Amortised Expenses	252.32	253.00	517.16
Interest expenses	173.33	-	-
Operating Profit before Working Capital Changes		163.00	309.84
<b>Working Capital Changes</b>	<b>887.38</b>	<b>748.00</b>	<b>1,252.54</b>
Trade and other receivables Including Inventory	-		
Trade and Other payables	62.25	5.65	(242.56)
<b>Cash Generated from Operations</b>	<b>(261.77)</b>	<b>136.76</b>	<b>52.96</b>
Interest paid	687.86	890.41	1,062.94
Taxation for the year	173.33	163.00	309.84
<b>Net Cash from Operating Activities</b>	<b>92.35</b>	<b>(21.00)</b>	<b>(18.82)</b>
<b>B. Cash Flow from Investing Activities:</b>	<b>422.18</b>	<b>748.41</b>	<b>772.92</b>
Purchase of Fixed Assets			
Investment	(700.89)	(630.00)	(706.82)
<b>Net Cash used in Investing Activities</b>	<b>-</b>	<b>(1.00)</b>	<b>(1.00)</b>
<b>C. Cash Flow From Financial Activities:</b>	<b>(700.89)</b>	<b>(631.00)</b>	<b>(707.82)</b>
Proceeds from Equity Shares	(0.00)	90.00	131.10
Net Proceeds from Long Term Borrowings	647.19	(206.20)	(148.90)
<b>Net Cash used in Financing Activities</b>	<b>647.19</b>	<b>(116.20)</b>	<b>(17.80)</b>
Net increase in cash and cash equivalents	368.48	1.41	46.30
Cash and Cash equivalents as at Beginning of the Year	99.05	53.00	52.76
Cash and Cash equivalents as at 30.09.2020	467.54	54.17	99.06





Vivo Bio Tech Ltd

8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate

Road No.1, Banjara Hills, Hyderabad-500034

E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

**Vivo Bio Tech Ltd.**  
Your Drug Discovery Partner

**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QTR AND HALF YEAR ENDED 30TH SEPTEMBER, 2020**

Rs. in Lacs

S.No.	PARTICULARS	QUARTER ENDED						HALF YEAR ENDED			Year Ended
		30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020				
		Un-Audited	Un-Audited	Un - Audited	Un-Audited	Un - Audited	Audited				
I	Revenue from operations	1,466.53	915.4	1354.44	2,381.93	2688.99	5535.22				
II	Other Income	0.00	0.00	2.93	-	2.93	5.32				
III	<b>Total Income</b>	<b>1,466.53</b>	<b>915.40</b>	<b>1357.37</b>	<b>2381.93</b>	<b>2691.92</b>	<b>5540.54</b>				
IV	<b>Expenses</b>										
	a) Increase/(decrease) in stock in trade and WIP	(101.32)	90.62	(33.56)	(10.70)	(129.60)	-234.23				
	b) Consumption of Raw materials	-	0.00	0.00	0.00	0.00	0.00				
	c) Purchase of traded goods	197.96	123.23	319.36	321.19	523.76	1089.97				
	d) Employees Cost	258.22	157.05	255.60	415.27	477.53	999.77				
	e) Depreciation and amortisation	130.92	126.42	126.45	257.34	252.89	517.16				
	f) Finance Cost	102.97	70.36	75.15	173.33	162.63	309.84				
	g)Administrative Expenditure	512.91	255.88	446.13	768.80	1072.65	2432.7				
	<b>Total</b>	<b>1,101.66</b>	<b>823.56</b>	<b>1189.13</b>	<b>1925.22</b>	<b>2359.86</b>	<b>5115.2</b>				
V	Profit Before Tax & Exceptional Item (III-IV)	364.86	91.84	168.25	456.70	332.07	425.33				
	Exceptional Item	0.00	0.00	0.00	0.00	0.00	0				
VI	Profit Before Tax	364.86	91.84	168.25	456.70	332.07	425.33				
VII	<b>Tax Expense</b>										
	a. Current Tax	73.99	18.36	19.16	92.35	82.81	112.33				
	b. Deffered tax	80.45	-24.28	(84.32)	56.17	(104.30)	-131.14				
	<b>Total Tax Expense</b>	<b>154.43</b>	<b>(5.92)</b>	<b>(65.17)</b>	<b>148.51</b>	<b>(21.50)</b>	<b>-18.81</b>				
	<b>Net Profit After Tax (V-VI)</b>	<b>210.43</b>	<b>97.76</b>	<b>233.41</b>	<b>308.19</b>	<b>353.56</b>	<b>444.15</b>				
VIII	Minority Interest	-	0.00	0.00	0.00	0.00	0.00				
IX	Other Comprehensive Income										
	a.Items that will be reclassified to profit or loss (Net of Tax)	-	0.00	0.00	0.00	0.00	0.00				
X	<b>Total other Comprehensive Income(VII+VIII+IX)</b>	<b>210.43</b>	<b>97.76</b>	<b>233.41</b>	<b>308.19</b>	<b>353.56</b>	<b>444.15</b>				
XI	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1,288.75	1288.75	1275.05	1288.75	1275.05	1288.75				
XII	<b>Earnings per equity share:</b>										
	1)Basic	1.63	0.76	1.83	2.39	2.77	3.45				
	2)Diluted	1.63	0.76	1.83	2.39	2.77	3.45				



Vivo Bio Tech Ltd

8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate

Road No.1, Banjara Hills, Hyderabad-500034

E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

**Vivo Bio Tech Ltd.**  
Your Drug Discovery Partner

Consolidated Cash Flow Statement for the Half Year Ended 30th September, 2020			
Particulars	Rs. In Lacs		
	As at 30.09.2020	As at 30.09.2019	As at 31.03.2020
	Un-Audited	Un-Audited	Audited
<b>A. Cash Flow from Operating Activities:</b>			
Net Profit/ (Loss) before taxation and extraordinary items	457	332	425
<b>Adjustments for:</b>			
Depreciation			
Amortised Expenses	257	253	517
Interest expenses		-	0
Operating Profit before Working Capital Changes	173	163	310
<b>Working Capital Changes</b>	<b>887</b>	<b>748</b>	<b>1,252</b>
Trade and other receivables Including Inventory	101	102	(154)
Trade and Other payables	(262)	357	53
<b>Cash Generated from Operations</b>	<b>727</b>	<b>1,207</b>	<b>1,152</b>
Interest paid	173	163	310
Taxation for the year	92	(21)	(19)
<b>Net Cash from Operating Activities</b>	<b>461</b>	<b>1,065</b>	<b>862</b>
<b>B. Cash Flow from Investing Activities:</b>			
Purchase of Fixed Assets	(701)	(947)	(1,023)
Investment	-	-	-
<b>Net Cash used in Investing Activities</b>	<b>(701)</b>	<b>(947)</b>	<b>(1,023)</b>
<b>C. Cash Flow From Financial Activities:</b>			
Proceeds from Equity Shares	(0)	90	131
Net Proceeds from Long Term Borrowings	611	(206)	78
<b>Net Cash used in Financing Activities</b>	<b>611</b>	<b>(116)</b>	<b>209</b>
<b>Net increase in cash and cash equivalents</b>	<b>372</b>	<b>2</b>	<b>48</b>
Cash and Cash equivalents as at Beginning of the Year	103	56	57
Cash and Cash equivalents as at 30.09.2020	474	58	105





Vivo Bio Tech Ltd  
 8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate  
 Road No.1, Banjara Hills, Hyderabad-500034  
 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

**Vivo Bio Tech Ltd.**  
 Your Drug Discovery Partner

Statement of Assets and Liabilities at at 30th September, 2020		Rs. in Lacs			
		Standalone		Consolidated	
Sl.No	Particulars	As At 30.09.2020	As At 31.03.2020	As At 30.09.2020	As At 31.03.2020
		Un-Audited	Audited	Un-Audited	Audited
I	<b>ASSETS</b>				
	<b>Non-Current Assets</b>				
	<b>Fixed Assets</b>				
	Property, Plant and Equipment	2,901.95	2,525.26	3,232.95	2,861.28
	Capital Work-In-Progress	167.03	15.36	167.03	15.36
	Intangible Assets	557.68	637.48	557.68	637.48
	<b>Financial Assets</b>				
	Non-Current Investments	4.00	4.00	-	-
	Long Term Loans and Advances	5.89	5.89	5.89	-
	Deferred Tax Asset	98.66	154.83	98.66	7.83
	<b>Total Non-Current Assets</b>	<b>3,735.22</b>	<b>3,342.81</b>	<b>4,062.22</b>	<b>3,521.94</b>
	<b>Current Assets</b>				
	Inventories	1,068.57	1,057.87	1,057.87	1,057.87
	<b>Financial Assets</b>				
	Trade Receivables	843.24	1,048.21	843.24	1,048.21
	Cash and cash equivalents	467.54	99.05	474.38	102.86
	Short term loans and advances	637.96	536.91	488.08	425.97
	Other current assets	88.20	57.24	88.20	57.24
	<b>Total Current Assets</b>	<b>3,105.51</b>	<b>2,799.28</b>	<b>2,951.77</b>	<b>2,692.15</b>
	<b>TOTAL ASSETS</b>	<b>6,840.73</b>	<b>5,987.27</b>	<b>7,013.99</b>	<b>6,214.09</b>
II	<b>EQUITY AND LIABILITIES</b>				
	<b>Equity</b>				
	Equity Share Capital	1,288.75	1,288.75	1,288.75	1,288.75
	Other Equity	2,328.16	2,014.95	2,321.85	2,013.66
	Money Received Against Share Warrants	-	-	-	-
	<b>Total Equity</b>	<b>3,616.91</b>	<b>3,303.70</b>	<b>3,610.60</b>	<b>3,302.41</b>
	<b>Liabilities</b>				
	<b>Non Current liabilities</b>				
	<b>Financial Liabilities</b>				
	Borrowings	1,388.23	741.04	1,580.21	968.74
	Defered Tax Liabilities(Net)	-	-	-	(154.83)
	Long term provisions	44.59	41.62	44.59	41.62
	<b>Total Non Current Liabilities</b>	<b>1,432.82</b>	<b>782.66</b>	<b>1,624.80</b>	<b>855.53</b>
	<b>Current Liabilities</b>				
	<b>Financial Liabilities</b>				
	Borrowings	1,389.71	1,467.48	1,389.71	1,467.48
	Trade Payable & Other Current Liabilities	85.16	391.37	85.16	391.37
	Provisions	316.13	196.89	316.36	197.31
	<b>Total Current Liabilities</b>	<b>1,791.00</b>	<b>2,055.74</b>	<b>1,791.23</b>	<b>2,056.15</b>
	<b>Total Equity &amp; Liabilities</b>	<b>6,840.73</b>	<b>5,987.27</b>	<b>7,026.63</b>	<b>6,214.09</b>

Place: Hyderabad  
 Date: 11th November, 2020

For Vivo Bio Tech Ltd

*M. Kalyan Ram*  
 Kalyan Ram Mangipudi  
 Chairperson & Whole Time Director  
 DIN:02012580



**Notes:**

1. The above Un-Audited Financial Results for the Second quarter and Half year ended 30<sup>th</sup> September, 2020 have been subject to a Limited Review by the Statutory Auditors are recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 11<sup>th</sup> November, 2020.
2. The above Un-Audited Financial Results have been prepared in accordance with the IND AS notified under the Companies (Indian Accounting Standards) Rules, 2015.
3. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
4. An Extract of the detailed format of Un-Audited Financial Results filed with stock exchange under Regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 will be published in Newspaper.
5. Previous year's/period's figures are rearranged/ regrouped wherever necessary.

For Vivo Bio Tech Limited



**M. Kalyan Ram**  
Chairperson & Whole Time Director  
DIN: 02012580

Place: Hyderabad  
Date: 11<sup>th</sup> November, 2020



**P C N & ASSOCIATES**

CHARTERED ACCOUNTANTS

Plot No. 12, "N Heights"

Ground Floor, Software Layout Unit

Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499

E-mail : pcnassociates@yahoo.com

To  
The Board of Directors,  
VIVO BIO TECH LIMITED,

**Limited Review Report for the quarter ended and half year ended 30<sup>th</sup> September 2020.**

1. We have reviewed the accompanying statement of unaudited standalone financial results ('the statement') of **VIVO BIO TECH LIMITED** (the 'Company') for the quarter ended and half year ended 30<sup>th</sup> September, 2020. This statement which is the responsibility of the Company's management and approved by the Board of Directors of the company at their meeting held on 11<sup>th</sup> November, 2020, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim financial reporting" ("Ind AS 34") prescribed under Section 133 of the companies Act, 2013 and other Accounting Principles generally accepted in India and which has been initiated by us for identification purposes. Our responsibility is to express a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



*Naveen*





**P C N & ASSOCIATES**

CHARTERED ACCOUNTANTS

Plot No. 12, "N Heights"

Ground Floor, Software Layout Unit

Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499

E-mail : pcnassociates@yahoo.com

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/ 62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates,

Chartered Accountants

Firm Registration No: 016016S

*M. Naveen*  
M Naveen

Partner

Membership No. 237316

UDIN:20237316AAAAGF3123



Place: Hyderabad

Date: 11-11-2020



**P C N & ASSOCIATES**  
CHARTERED ACCOUNTANTS  
Plot No. 12, "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

To  
The Board of Directors,  
VIVO BIO TECH LIMITED

**Limited Review Report on Consolidated Financial Results for the quarter ended and half year ended 30<sup>th</sup>September 2020.**

1. We have reviewed the accompanying Consolidated Unaudited Financial Results ("the Statement") of **VIVO BIO TECH LIMITED**("the Parent") and its subsidiaries (the Parent and its-subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income for the quarter ended and half year ended 30<sup>th</sup>September 2020 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors at their meeting held on 11th November 2020, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.







**P C N & ASSOCIATES**  
CHARTERED ACCOUNTANTS  
Plot No. 12, "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

4. The Statement includes the results of the following entities

Subsidiaries

1. Vivo bio discovery services private limited.
  2. Surlogic Life Consultancy Private Limited.
  3. Vivobio Labs Private Limited
  4. Vivo Bio Consulting Services Private Limited ( Formerly known as Donakanti Consultancy Services Private Limited)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of four subsidiaries, included in the consolidated unaudited financial results, whose interim financial information reflect total assets of Rs.360.77 Lakhs before elimination, total revenues of Rs. NIL total net loss of Rs.5.03 Lakhs and total comprehensive income of Rs.(5.03) lakhs for the quarter ended 30<sup>th</sup> September 2020, as considered in the consolidated unaudited financial results. These interim financial information have been reviewed by other auditor's whose report has been furnished to us by the Management and our conclusion on the Statement, insofar as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditor and the procedures performed by us stated in paragraph 3 above.


Our conclusion on the statement is not modified in respect of the above matter.

For P C N & Associates,  
Chartered Accountants  
Firm Registration No. 015016

*M Naveen*

M Naveen  
Partner

Membership No. 237316  
UDIN:20237316AAAAGG3134



Place: Hyderabad  
Date: 11-11-2020